MAPK3 and non-small cell lung carcinoma: The pivotal ERK1/2-MAPK and PI3K/AKT pathways play critical roles in gefitinib/erlotinib-induced antitumor effects in NSCLC cell lines and tumors with EGFR addiction [44,45].